Ali Montazeri

Last updated

Ali Montazeri (Ali Montazeri Moghaddam, born September 2, 1958) is an Iranian public health scientist at the Health Metrics Research Center of the Iranian Institute for Health Sciences Research. [1] He is editor-in-chief of an Iranian health journal: Payesh (Health Monitor-the journal of Iranian Institute for Health Sciences Research), [2] the associate editor of Health and Quality of Life Outcomes [3] up to Feb. 2024, and academic editor for PLOS One . [4] He has been three times the director of Academic Center for Education, Culture and Research. [5]

Contents

Education

Montazeri received his PhD from University of Glasgow. His thesis concerned the quality of life in lung cancer patients, and was jointly supervised by Charles Gillis and James McEwen. [6]

Research

1. Quality of life, Breast cancer: Montazeri published a paper in 2004 that found knowledge of cancer diagnosis does not change how a person fills out a questionnaire about his or her quality of life. [7] In a 2012 book chapter, he proposed that research be conducted to see how quality of life in people with cancer is affected by the way a cancer diagnosis is disclosed and how the person's level of education affects quality of life. [8]

He also published papers in 2002, 2003, and 2015 about the epidemiology of breast cancer and breast cancer preventive behaviors such as breast self-examination [9] [10] [11]

In 2008 and 2009, he published two reviews of the literature on the quality of life in women with breast cancer which are still receiving considerable attention . [12] [13]

Recently he published an updated review on the quality of life in breast cancer patients [14] and a systematic review of qualitative studies on the topic. [15]

2. Guideline for reporting bibliometric reviews (analysis): He and his colleagues developed a guideline for reporting bibliometric reviews, namely the BIBLIO. [16] Similar to many guidelines it provides a checklist for transparency in reporting bibliometric reviews of the literature.

3. Health literacy: Montazeri also contributed to the development of several instruments for measuring health literacy which are available for use with adults - HELIA [17], adolescents - HELMA [18], oral health -OHLAQ [19], and postpartum depression - PoDLiS.[20] In a recent publication he and his colleagues initiated a comprehensive review of existing measures for health literacy.[21]

Related Research Articles

<span class="mw-page-title-main">Mammography</span> Process of using low-energy X-rays to examine the human breast for diagnosis and screening

Mammography is the process of using low-energy X-rays to examine the human breast for diagnosis and screening. The goal of mammography is the early detection of breast cancer, typically through detection of characteristic masses or microcalcifications.

eHealth describes healthcare services which are supported by digital processes, communication or technology such as electronic prescribing, Telehealth, or Electronic Health Records (EHRs). The use of electronic processes in healthcare dated back to at least the 1990s. Usage of the term varies as it covers not just "Internet medicine" as it was conceived during that time, but also "virtually everything related to computers and medicine". A study in 2005 found 51 unique definitions. Some argue that it is interchangeable with health informatics with a broad definition covering electronic/digital processes in health while others use it in the narrower sense of healthcare practice using the Internet. It can also include health applications and links on mobile phones, referred to as mHealth or m-Health. Key components of eHealth include electronic health records (EHRs), telemedicine, health information exchange, mobile health applications, wearable devices, and online health information. These technologies enable healthcare providers, patients, and other stakeholders to access, manage, and exchange health information more effectively, leading to improved communication, decision-making, and overall healthcare outcomes.

<span class="mw-page-title-main">HER2</span> Mammalian protein found in humans

Receptor tyrosine-protein kinase erbB-2 is a protein that normally resides in the membranes of cells and is encoded by the ERBB2 gene. ERBB is abbreviated from erythroblastic oncogene B, a gene originally isolated from the avian genome. The human protein is also frequently referred to as HER2 or CD340.

<span class="mw-page-title-main">Cancer survivor</span> Person with cancer who is still alive

A cancer survivor is a person with cancer of any type who is still living. Whether a person becomes a survivor at the time of diagnosis or after completing treatment, whether people who are actively dying are considered survivors, and whether healthy friends and family members of the cancer patient are also considered survivors, varies from group to group. Some people who have been diagnosed with cancer reject the term survivor or disagree with some definitions of it.

In medicine, patient compliance describes the degree to which a patient correctly follows medical advice. Most commonly, it refers to medication or drug compliance, but it can also apply to other situations such as medical device use, self care, self-directed exercises, or therapy sessions. Both patient and health-care provider affect compliance, and a positive physician-patient relationship is the most important factor in improving compliance. Access to care plays a role in patient adherence, whereby greater wait times to access care contributing to greater absenteeism. The cost of prescription medication also plays a major role.

Psycho-oncology is an interdisciplinary field at the intersection of physical, psychological, social, and behavioral aspects of the cancer experience for both patients and caregivers. Also known as psychiatric oncology or psychosocial oncology, researchers and practitioners in the field are concerned with aspects of individuals' experience with cancer beyond medical treatment, and across the cancer trajectory, including at diagnosis, during treatment, transitioning to and throughout survivorship, and approaching the end-of-life. Founded by Jimmie Holland in 1977 via the incorporation of a psychiatric service within the Memorial Sloan Kettering Cancer Center in New York, the field has expanded drastically since and is now universally recognized as an integral component of quality cancer care. Cancer centers in major academic medical centers across the country now uniformly incorporate a psycho-oncology service into their clinical care, and provide infrastructure to support research efforts to advance knowledge in the field.

A patient-reported outcome (PRO) is a health outcome directly reported by the patient who experienced it. It stands in contrast to an outcome reported by someone else, such as a physician-reported outcome, a nurse-reported outcome, and so on. PRO methods, such as questionnaires, are used in clinical trials or other clinical settings, to help better understand a treatment's efficacy or effectiveness. The use of digitized PROs, or electronic patient-reported outcomes (ePROs), is on the rise in today's health research setting.

<span class="mw-page-title-main">Roxana Moslehi</span> Genetic epidemiologist

Roxana Moslehi is an Iranian-born genetic epidemiologist.

Bovine leukemia virus (BLV) is a retrovirus which causes enzootic bovine leukosis in cattle. It is closely related to the human T‑lymphotropic virus type 1 (HTLV-I). BLV may integrate into the genomic DNA of B‑lymphocytes as a DNA intermediate, or exist as unintegrated circular or linear forms. Besides structural and enzymatic genes required for virion production, BLV expresses the Tax protein and microRNAs involved in cell proliferation and oncogenesis. In cattle, most infected animals are asymptomatic; leukemia is rare, but lymphoproliferation is more frequent (30%).

<span class="mw-page-title-main">Breast cancer screening</span> Medical screening of asymptomatic, healthy women for breast cancer

Breast cancer screening is the medical screening of asymptomatic, apparently healthy women for breast cancer in an attempt to achieve an earlier diagnosis. The assumption is that early detection will improve outcomes. A number of screening tests have been employed, including clinical and self breast exams, mammography, genetic screening, ultrasound, and magnetic resonance imaging.

TOX high mobility group box family member 3, also known as TOX3, is a human gene.

<span class="mw-page-title-main">Quality of life (healthcare)</span> Notion in healthcare

In general, quality of life is the perceived quality of an individual's daily life, that is, an assessment of their well-being or lack thereof. This includes all emotional, social and physical aspects of the individual's life. In health care, health-related quality of life (HRQoL) is an assessment of how the individual's well-being may be affected over time by a disease, disability or disorder.

<span class="mw-page-title-main">Cancer screening</span> Method to detect cancer

The objective of cancer screening is to detect cancer before symptoms appear, involving various methods such as blood tests, urine tests, DNA tests, and medical imaging. The purpose of screening is early cancer detection, to make the cancer easier to treat and extending life expectancy. In 2019, cancer was the second leading cause of death globally; more recent data is pending due to the COVID-19 pandemic.

Decision aids are interventions or tools designed to facilitate shared decision making and patient participation in health care decisions.

The General Health Questionnaire (GHQ) is a psychometric screening tool to identify common psychiatric conditions. It has been translated and validated in at least two languages in addition to English, including Spanish and Persian. The latter used in different fields and generations. Also, using GHQ was beneficial in high-tech systems personnel.

A variant of uncertainsignificance (VUS) is a genetic variant that has been identified through genetic testing but whose significance to the function or health of an organism is not known. Two related terms are "gene of uncertain significance" (GUS), which refers to a gene that has been identified through genome sequencing but whose connection to a human disease has not been established, and "insignificant mutation", referring to a gene variant that has no impact on the health or function of an organism. The term "variant' is favored in clinical practice over "mutation" because it can be used to describe an allele more precisely. When the variant has no impact on health, it is called a "benign variant". When it is associated with a disease, it is called a "pathogenic variant". A "pharmacogenomic variant" has an effect only when an individual takes a particular drug and therefore is neither benign nor pathogenic.

<span class="mw-page-title-main">Sofosbuvir/daclatasvir</span> Combination drug

Daclatasvir/sofosbuvir is a two-drug combination for the treatment of hepatitis C. It is given as a single daily pill containing daclatasvir, a viral NS5A inhibitor, and sofosbuvir, a nucleotide inhibitor of the viral RNA polymerase NS5B.

<span class="mw-page-title-main">Amit Dutt</span> Indian academic (born 1973)

Amit Dutt is an Indian scientist, geneticist and the principal investigator at Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) of Tata Memorial Centre. Known for his studies on Fibroblast growth factor receptor, Dutt is a Wellcome Trust / DBT India Alliance Intermediate Fellow. The Council of Scientific and Industrial Research, the apex agency of the Government of India for scientific research, awarded him the Shanti Swarup Bhatnagar Prize for Science and Technology, one of the highest Indian science awards, for his contributions to medical sciences in 2017.

<span class="mw-page-title-main">Adaptive design (medicine)</span> Concept in medicine referring to design of clinical trials

In an adaptive design of a clinical trial, the parameters and conduct of the trial for a candidate drug or vaccine may be changed based on an interim analysis. Adaptive design typically involves advanced statistics to interpret a clinical trial endpoint. This is in contrast to traditional single-arm clinical trials or randomized clinical trials (RCTs) that are static in their protocol and do not modify any parameters until the trial is completed. The adaptation process takes place at certain points in the trial, prescribed in the trial protocol. Importantly, this trial protocol is set before the trial begins with the adaptation schedule and processes specified. Adaptions may include modifications to: dosage, sample size, drug undergoing trial, patient selection criteria and/or "cocktail" mix. The PANDA provides not only a summary of different adaptive designs, but also comprehensive information on adaptive design planning, conduct, analysis and reporting.

References

  1. ↑ "CV at the Institute of Health Sciences" (PDF). Retrieved 21 February 2017. Linked from Departmental web page
  2. ↑ Payesh Health Monitor, retrieved 2017-02-21.
  3. ↑ http://hqlo.biomedcentral.com, retrieved 2017-02-21.
  4. ↑ "PLOS ONE".
  5. ↑ "Montazeri Prominent In Cancer Studies". Archived from the original on 2021-09-27. Retrieved 2023-01-16.
  6. ↑ Montazeri, Ali (August 1996). Quality of Life in Patients with Lung Cancer: An Epidemiological Study (PDF) (PhD). University of Glasgow.
  7. ↑ Montazeri, A; Hole, DJ; Milroy, R; McEwen, J; Gillis, CR (2004-05-19). "Does knowledge of cancer diagnosis affect the quality of life? A methodological challenge". BMC Cancer. 4: 21. doi: 10.1186/1471-2407-4-21 . PMC   420242 . PMID   15151702.
  8. ↑ Montazeri, Ali (2012). "Cancer Disclosure, Health-Related Quality of Life, and Psychological Distress: An Iranian Perspective". In Surbone, Antonella; Zwitter, Matjaž; Rajer, Mirjana; Stiefel, Richard (eds.). New Challenges in Communication with Cancer Patients. New York: Springer. pp. 403–409. doi:10.1007/978-1-4614-3369-9_33. ISBN   978-1-4614-3369-9.
  9. ↑ Ebrahimi, M; Vahdaninia, M; Montazeri, A (2002). "Risk factors for breast cancer in Iran: a case-control study". Breast Cancer Research. 4 (5): R10. doi: 10.1186/bcr454 . PMC   125302 . PMID   12223127.
  10. ↑ Montazeri, A; Haji-Mahmoodi, M; Jarvandi, S (June 2003). "Breast self-examination: do religious beliefs matter? A descriptive study". Journal of Public Health Medicine. 25 (2): 154–5. doi: 10.1093/pubmed/fdg031 . PMID   12848405.
  11. ↑ Montazeri, A; Ebrahimi, M; Mehrdad, N; Ansari, M; Sajadian, A (2015-09-28). "Delayed presentation in breast cancer: a study in Iranian women". BMC Women's Health. 3 (1): 4. doi: 10.1186/1472-6874-3-4 . PMC   166160 . PMID   12846932.
  12. ↑ Montazeri, A (29 August 2008). "Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007". Journal of Experimental & Clinical Cancer Research. 27 (1): 32. doi: 10.1186/1756-9966-27-32 . PMC   2543010 . PMID   18759983.
  13. ↑ Montazeri, A (2009). "Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008". Health Qual Life Outcomes. 7: 102. doi: 10.1186/1477-7525-7-102 . PMC   2805623 . PMID   20030832.
  14. ↑ Mokhtari-Hesari, Parisa; Montazeri, Ali (December 2020). "Health-related quality of life in breast cancer patients: review of reviews from 2008 to 2018". Health and Quality of Life Outcomes. 18 (1). doi: 10.1186/s12955-020-01591-x . ISSN   1477-7525. PMC   7552560 . PMID   33046106.
  15. ↑ Heidary, Zohreh; Ghaemi, Marjan; Hossein Rashidi, Batool; Kohandel Gargari, Omid; Montazeri, Ali (April 2023). "Quality of Life in Breast Cancer Patients: A Systematic Review of the Qualitative Studies". Cancer Control. 30. doi:10.1177/10732748231168318. ISSN   1073-2748. PMC   10236425 . PMID   37082898.
  16. ↑ Montazeri, Ali; Mohammadi, Samira; M.Hesari, Parisa; Ghaemi, Marjan; Riazi, Hedyeh; Sheikhi-Mobarakeh, Zahra (2023-12-15). "Preliminary guideline for reporting bibliometric reviews of the biomedical literature (BIBLIO): a minimum requirements". Systematic Reviews. 12 (1). doi: 10.1186/s13643-023-02410-2 . ISSN   2046-4053. PMC   10722750 . PMID   38102710.

17. Tavousi M, Haeri-Mehrizi A, Rakhshani F, Rafiefar S, Soleymanian A, Sarbandi F, Ardestani M, Ghanbari S, Montazeri A. Development and validation of a short and easy-to-use instrument for measuring health literacy: the Health Literacy Instrument for Adults (HELIA). BMC Public Health. 2020 May 12;20(1):656. doi: 10.1186/s12889-020-08787-2. PMID: 32397970; PMCID: PMC7216550.

18. Ghanbari S, Ramezankhani A, Montazeri A, Mehrabi Y. Health Literacy Measure for Adolescents (HELMA): Development and Psychometric Properties. PLoS One. 2016 Feb 16;11(2):e0149202. doi: 10.1371/journal.pone.0149202. PMID: 26881933; PMCID: PMC4755574.

19. Naghibi Sistani MM, Montazeri A, Yazdani R, Murtomaa H. New oral health literacy instrument for public health: development and pilot testing. J Investig Clin Dent. 2014 Nov;5(4):313-21. doi: 10.1111/jicd.12042. Epub 2013 Apr 4. PMID: 23559571.

20. Mirsalimi F, Ghofranipour F, Noroozi A, Montazeri A. The postpartum depression literacy scale (PoDLiS): development and psychometric properties. BMC Pregnancy Childbirth. 2020 Jan 3;20(1):13. doi: 10.1186/s12884-019-2705-9. PMID: 31900131; PMCID: PMC6942397.

21. Tavousi M, Mohammadi S, Sadighi J, Zarei F, Kermani RM, Rostami R, Montazeri A. Measuring health literacy: A systematic review and bibliometric analysis of instruments from 1993 to 2021. PLoS One. 2022 Jul 15;17(7):e0271524. doi: 10.1371/journal.pone.0271524. PMID: 35839272; PMCID: PMC9286266.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.